The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

Documents similaires

• The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  par: Beale, R, et autres
  Publié: (2004)
• Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  par: Vincent, J, et autres
  Publié: (2004)
• Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
  par: Levy, Howard, et autres
  Publié: (2005)
• Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis
  par: Laterre, Pierre-François, et autres
  Publié: (2008)
• Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
  par: Dhainaut, J, et autres
  Publié: (2008)